The global immunohistochemistry market size was valued at USD 1.6 billion in 2017. It is projected to expand at a CAGR of 8.8%in terms of revenue over the forecast period. Immunohistochemistry (IHC), as a crucial application of monoclonal and polyclonal antibodies helps understand tissue distribution of an antigen. It is extensively used for cancer diagnosis as it helps determine the presence of tumor antigens and understand if the tumor is benign or malignant. Rising prevalence of chronic diseases and rapidly growing elderly population are the primary factors contributing to market growth.
The number of cancer patients is on the rise. This factor is expected to cause a surge in demand for effective diagnostics. IHC plays a vital role in disease diagnosis by predicting prognosis of tumors. It is used in identification of enzymes, tumor suppressor genes, antigens, and tumor cell proliferation, among others.
Immunohistochemistry is more advantageous than traditional enzyme staining techniques since it involves specific antigen-antibody reactions. Traditional techniques identify only a partial amount of tissue structures, proteins, and enzymes. Thus, IHC is widely used in clinical diagnostics and medical research laboratories.
Other factors driving the immunohistochemistry market include rapid increase in healthcare spending and a changing healthcare infrastructure with better medical practice and care facilities. Aging is associated with infections and autoimmune diseases due to a weakening immune system. Rise in geriatric population leads to increased need for IHC techniques, thereby driving the market.
On the basis of product, the market is categorized into antibodies, reagents, equipment, and kits. Antibodies emerged as the dominant product segment in 2017. Therapeutic monoclonal antibodies and antibody-related products such as antibody fragments, Fc-fusion proteins, and antibody-drug conjugates have become the leading product class in the market. In addition, increasing adoption of targeted immunotherapy for a safer, better targeted, and more effective treatment is anticipated to result in high demand for antibodies. Growing burden of chronic diseases and high demand for immune therapeutics will further drive demand in the coming years.
Equipment also held significant market share in terms of revenue in 2017 owing to introduction of technologically advanced instruments such as slide scanners. These devices are designed to analyze multiple specimens post staining in patient samples.
On the basis of application, the market for immunohistochemistry is bifurcated into diagnostics and drug testing. The diagnostics segment is further divided into cancer, diabetes, autoimmune, cardiovascular, infectious, and nephrological diseases. IHC techniques play a vital role in drug development process for testing drug efficacy through detection of up or down regulation in disease targets.
In 2017, cancer accounted for the largest share in diagnostics owing to high disease prevalence. According to the American Cancer Society, around 1,688,780 new cases of cancer were reported in 2017. In addition, the WHO’s International Agency for Research on Cancer (IARC) predicts the global burden of cancer to multiply and reach22 million in the coming years. It was estimated at 14 million new cancer cases per year in 2012. The disease is estimated to account for a rise of about 70%.
By end use, the market is divided into research institutions, hospitals and diagnostic laboratories, and others. Hospitals and diagnostic laboratories segment held the largest market share in terms of revenue in 2017. Immunohistochemistry is an ancillary methodology frequently used for diagnostic and research purposes. Technological advancements such as automated sample preparation and digital pathology have added considerable value.
The research institute segment held a significant revenue share in 2017. IHC has various advantages over traditional staining techniques. Hence, it is an important technique used in research institutes.
North America held the dominant share of the market for immunohistochemistry in 2017. Gradual maturity of biotech market and rapid commercialization of IHC are some of the major factors driving the regional growth. However, the capital-intensive nature that requires long R&D and approval cycles may hinder market growth over the forecast period. Nevertheless, growing adoption for the diagnosis of tumors of ambiguous origin contributes to regional dominance in the years to come.
Asia Pacific is expected to be the fastest growing segment, owing to rapid growth of biotech industry in developed economies such as Japan and Australia coupled with emerging economies like India and China. The Indian biotech industry witnessed year over year (YOY) growth of 57% in the financial year 2016, compared to the previous year. This growth rate is expected to drive the IHC market. Furthermore, high prevalence of chronic diseases and rising geriatric population are some of the significant factors driving the regional growth.
Some of the key players in the market include Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; Thermo Fisher Scientific, Inc.
Market players focus on alliances, strategic planning, new product launches, and research activities to achieve extensive growth. They are also adopting mergers and acquisitions to sustain the high competition. For instance, in 2017, PerkinElmer announced the launch of Vectra Polaris Automated Quantitative Pathology Imaging System. This device is designed to provide researchers with an enhanced understanding of cancer immunotherapy approaches.
|
Attribute |
Details |
|
Base year for estimation |
2017 |
|
Actual estimates/Historical data |
2014 - 2016 |
|
Forecast period |
2018 - 2025 |
|
Market representation |
Revenue in USD Million & CAGR from 2018 to 2025 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
|
Country scope |
U.S., Canada, U.K., Germany, Japan, China, India, Brazil, Mexico, South Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
|
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global immunohistochemistry market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Antibodies
Primary Antibodies
Secondary Antibodies
Equipment
Slide Staining Systems
Tissue Microarrays
Tissue Processing Systems
Slide Scanners
Others
Reagents
Histological Stains
Blocking Sera and Reagents
Chromogenic Substrates
Fixation Reagents
Stabilizers
Organic Solvents
Proteolytic Enzymes
Diluents
Kits
Application Outlook (Revenue, USD Million, 2014 - 2025)
Diagnostics
Cancer
Infectious Diseases
Cardiovascular Diseases
Autoimmune Diseases
Diabetes Mellitus
Nephrological Diseases
Drug Testing
End Use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals and Diagnostic Laboratories
Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
